Not currently recruiting at University of California Health
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Summary
- Eligibility
- for people ages up to 21 years (full criteria)
- Location
- at UCLA
- Dates
- study startedestimated completion
- Principal Investigator
- by Noah Noah Federman (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Noah Noah Federman (ucla)
Dr. Noah Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center. Dr. Federman specializes in treating children, adolescents and young adults with these aggressive cancers.
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors
- ID
- NCT04238819
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 117 study participants
- Last Updated